Copyright ©ERS Journals Ltd 2007 Effect of anti-PcrV antibody in a murine chronic airway Pseudomonas aeruginosa infection model1 Second Dept of Internal Medicine, Nagasaki University School of Medicine, Nagasaki, Japan. 2 Dept of Anesthesia and Critical Care, University of California, San Francisco, CA, USA. 3 Both authors contributed equally to this study. CORRESPONDENCE: K. Yanagihara, The Second Dept of Internal Medicine, Nagasaki University School of Medicine, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan. Fax: 81 958497285. E-mail: kyana-ngs{at}umin.ac.jp Keywords: Anti-PcrV antibody, chronic airway infection, Pseudomonas aeruginosa, type III secretion system
Received: November 13, 2006
Pseudomonas aeruginosa is one of the most important pathogens in patients with chronic airway conditions, such as cystic fibrosis and diffuse panbronchiolitis. Type III secretion system-mediated virulence factors contribute to the lung damage in chronic P. aeruginosa infection.
The effects of the anti-PcrV immunoglobulin (Ig)G, which blocks the type III secretion system, were evaluated in a mouse model of chronic P. aeruginosa infection. On bacteriological examination, anti-PcrV IgG showed no bactericidal effects. On bronchoalveolar lavage fluid (BALF) analysis, total cell number and neutrophil ratios in the anti-PcrV IgG-treated groups were lower than those in the control group. In addition, macrophage inflammatory protein-2, tumour necrosis factor-
These data suggest that anti-PcrV immunoglobulin G reduces the inflammatory reaction caused by chronic Pseudomonas aeruginosa respiratory infection and may be useful in treating respiratory diseases.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||